Paper19916992
Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.
Damle BD and 5 others. Br J Clin Pharmacol, 2009. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Papers, record 19916992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19916992
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aryl Hydrocarbon Hydroxylases | Major topic |
| HIV Protease Inhibitors | Major topic |
| Nelfinavir | Major topic |
| Adult | |
| Cytochrome P-450 CYP2C19 | |
| Female | |
| Humans | |
| Male | |
| Metabolic Clearance Rate | |
| Middle Aged | |
| Polymorphism, Genetic | |
| Young Adult |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18231117 | Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. | Clin Pharmacol Ther | 2008 | https://conductscience.org/library/papers/18231117 | PubMed |
| 2 | 18154473 | Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. | Pharmacotherapy | 2008 | https://conductscience.org/library/papers/18154473 | PubMed |
| 3 | 11809184 | Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. | Lancet | 2002 | https://conductscience.org/library/papers/11809184 | PubMed |
| 4 | 15614709 | Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. | Clin Infect Dis | 2005 | https://conductscience.org/library/papers/15614709 | PubMed |
| 5 | 15673746 | Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15673746 | PubMed |
| 6 | 17922881 | Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. | Br J Clin Pharmacol | 2008 | https://conductscience.org/library/papers/17922881 | PubMed |
| 7 | 12222994 | Clinical significance of the cytochrome P450 2C19 genetic polymorphism. | Clin Pharmacokinet | 2002 | https://conductscience.org/library/papers/12222994 | PubMed |
| 8 | 10971203 | The CYP2C19 enzyme polymorphism. | Pharmacology | 2000 | https://conductscience.org/library/papers/10971203 | PubMed |
| 9 | 19246729 | Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. | J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19246729 | PubMed |
| 10 | 15750390 | An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. | AIDS | 2005 | https://conductscience.org/library/papers/15750390 | PubMed |
| 11 | 16225378 | Nelfinavir: a review of its use in the management of HIV infection. | Drugs | 2005 | https://conductscience.org/library/papers/16225378 | PubMed |
| 12 | 11257019 | Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11257019 | PubMed |
| 13 | 16267764 | Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. | J Infect Dis | 2005 | https://conductscience.org/library/papers/16267764 | PubMed |
| 14 | 15448116 | Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. | Drug Metab Dispos | 2004 | https://conductscience.org/library/papers/15448116 | PubMed |
| 15 | 16842404 | The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. | Br J Clin Pharmacol | 2006 | https://conductscience.org/library/papers/16842404 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39832006 | Validating the accuracy of mathematical model-based pharmacogenomics dose prediction with real-world data. | Eur J Clin Pharmacol | 2025 | https://conductscience.org/library/papers/39832006 | PubMed |
| 31071346 | A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. | Pharmacol Ther | 2019 | https://conductscience.org/library/papers/31071346 | PubMed |
| 29577081 | Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women. | Int J HIV AIDS Res | 2017 | https://conductscience.org/library/papers/29577081 | PubMed |
| 25752914 | Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. | Br J Clin Pharmacol | 2015 | https://conductscience.org/library/papers/25752914 | PubMed |
| 23319287 | In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. | AAPS J | 2013 | https://conductscience.org/library/papers/23319287 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP2C19 | 1557 | PubTator's text mining | https://conductscience.org/library/genes/1557 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19916992
GET https://conductscience.org/api/papers/v1/19916992/authors